SANOFI US SERVICES INC. for SANOFI US SERVICES INC
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare Part D Annual Call Letter, issues related to formulary specialty tiers and coverage of prescription drugs; reporting measures under Medicare Part A related to hospital acquired conditions; and anticoagulation reimbursement under Medicare Part B
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| MARK COIN | — |
Pharmacy PHA
Issues related to the final regulations implementing those provisions of HR4896 "National Defense Authorization Act for FY2008" related to TRICARE retail pharmacy sales.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD M HODGE | — |
Taxation/Internal Revenue Code TAX
Extension of the U.S. R&D tax credit including all such provisions in HR 422 "To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit" and S1203 "Grow Research Opportunities with Tax Credits' Help Act" or "GROWTH Act" ; international tax treaties and the ratification of the Second Protocol to the Income Tax Treaty between the U.S. and France.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD GREISSING | — |
| ANN TAYLOR | — |
Copyright/Patent/Trademark CPT
All provisions of S369 "Protecting Access to Affordable Generic Drugs Act of 2009" and HR1706 "Protecting Consumer Access to Generic Drugs Act of 2009"; all provisions of S515 "The Patent Reform Act of 2009" and HR1260 "The Patent Reform Act of 2009"
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| MARK COIN | — |
| EDDIE D EVANS | — |
| SAIRA SULTAN | — |
Health Issues HCR
Coverage and payment issues for pharmaceuticals under consideration for draft legislation for healthcare reform; issues related to the importation of prescription drugs in amendments to the draft legislation "Affordable Health Choices Act"; issues related to a regulatory pathway and reimburesment for follow on biologics, including such provisions in HR 1548 "Pathway for Biosimilars Act"; issues related to awareness of the company's Access to Medicines Program; all provisions of H. Res. 231 "Supporting the goals and ideals of 'Deep Vein Thrombosis Awareness Month'"; general issues related to the Medicare Part D program
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| MARK COIN | — |
| EDDIE D EVANS | — |
| EDWARD GREISSING | — |
| RICHARD M HODGE | — |
| SAIRA SULTAN | — |
| ANN TAYLOR | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.